2CV Stock Chart & Stats
€2.68
€0.00(0.00%)
At close: 4:00 PM EST
€2.68
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.14 - €2.92
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€4.93B
Enterprise Value€6.06K
Total Cash (Recent Filing)€75.03M
Total Debt (Recent Filing)€1.52B
Price to Earnings (P/E)32.9
Beta0.83
Next Earnings
Aug 04, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding1,954,852,000
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio-7.33
Price to Book (P/B)4.36
Price to Sales (P/S)2.66
P/FCF Ratio19.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.49Price Target Upside30.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€30.07M
Bulls Say, Bears Say
Bulls Say
Consistent Organic Revenue GrowthSustained organic growth across multiple chronic-care categories signals durable demand for recurring consumables and services. Multi-year >5% growth (ex‑InnovaMatrix) plus 2026 guidance of 5–7% supports predictable revenue expansion and underpins planning for capacity and product investments.
Operating Margin ExpansionMeaningful and sustained EBIT margin improvement reflects structural productivity, pricing and portfolio mix progress rather than one-off gains. Higher operating margins increase cash flow potential, fund growth CapEx, support dividends/buybacks and provide a buffer against inflation and execution risks.
Strong Cash Generation And Capital AllocationConsistently positive free cash flow and high conversion rates enable disciplined reinvestment and shareholder returns. Robust FCF funds growth CapEx, supports a progressive dividend and material buybacks while maintaining the ability to service debt and pursue strategic launches over the medium term.
Bears Say
Rising LeverageHigher leverage reduces financial flexibility and increases sensitivity to earnings volatility or higher interest rates. Even with management targeting ~2x net debt/EBITDA, elevated debt levels constrain capital allocation optionality and heighten refinancing and covenant risk during operational setbacks.
FDA Complaints/CAPA Warning LetterRegulatory process deficiencies are a structural risk for a medical-device business: remediation can be prolonged and costly, may limit new product rollouts or sales channels, and can damage customer trust with hospitals and payors, affecting adoption and long-term growth.
InnovaMatrix Reimbursement Shock & ImpairmentA major reimbursement-driven collapse following acquisition shows vulnerability to payer actions. Such structural reimbursement risk can permanently reduce returns on M&A, create multi-year revenue headwinds (~2% in 2026) and complicate commercial recovery even after salesforce or channel fixes.
ConvaTec News
2CV FAQ
What was ConvaTec’s price range in the past 12 months?
ConvaTec lowest stock price was €2.14 and its highest was €2.92 in the past 12 months.
What is ConvaTec’s market cap?
ConvaTec’s market cap is €4.93B.
When is ConvaTec’s upcoming earnings report date?
ConvaTec’s upcoming earnings report date is Aug 04, 2026 which is in 10 days.
How were ConvaTec’s earnings last quarter?
ConvaTec released its earnings results on Feb 24, 2026. The company reported €0.085 earnings per share for the quarter, missing the consensus estimate of €0.088 by -€0.003.
Is ConvaTec overvalued?
According to Wall Street analysts ConvaTec’s price is currently Undervalued.
Does ConvaTec pay dividends?
ConvaTec does not currently pay dividends.
What is ConvaTec’s EPS estimate?
ConvaTec’s EPS estimate is 0.07.
How many shares outstanding does ConvaTec have?
ConvaTec has 1,954,852,000 shares outstanding.
What happened to ConvaTec’s price movement after its last earnings report?
ConvaTec reported an EPS of €0.085 in its last earnings report, missing expectations of €0.088. Following the earnings report the stock price went up 9.938%.
Which hedge fund is a major shareholder of ConvaTec?
Currently, no hedge funds are holding shares in DE:2CV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ConvaTec Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€3.49 (30.17% Upside)
€3.49 (30.17% Upside)
Insider Transactions
Bought Shares
Worth €176.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.50%
12-Months-Change
Fundamentals
Return on Equity
2.41%
Trailing 12-Months
Asset Growth
0.16%
Trailing 12-Months
Company Description
ConvaTec
ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, where it provides specialized dressings and skin care items for managing acute and chronic wounds that arise from conditions like diabetes, immobility, venous disease, traumatic injuries, burns, or surgical recovery. The company is also a key provider in ostomy care, delivering essential devices, accessories, and support services for individuals living with a stoma due to conditions such as colorectal cancer, inflammatory bowel disease, bladder cancer, and obesity. Beyond wound and ostomy solutions, ConvaTec's portfolio extends to continence and critical care. This includes intermittent urinary catheters and related products designed to assist individuals with urinary continence issues stemming from spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders. They also furnish equipment for intensive care units and hospital settings, alongside advanced systems for managing acute fecal incontinence and monitoring urine output and intra-abdominal pressure. Additionally, ConvaTec supplies various disposable medical devices, such as wound drainage systems, urine collection bags, airway management tools, gastroenterology tubes, and securement devices. The company manufactures disposable infusion sets for insulin pumps used in diabetes treatment, as well as for other continuous infusion therapies. These products reach pharmacies, hospitals, and both acute and post-acute healthcare providers directly, or through a network of distributors and wholesalers, catering to healthcare professionals, patients, and other manufacturers. Established in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
2CV Stock 12 Month Forecast
Average Price Target
€3.49
▲(30.17% Upside)






